LONDON--(BUSINESS WIRE)--May 1, 2018--Market research firm has announced the release of their latest report on the . This new report will provide expert market insights for the forecast period 2018-2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180501005742/en/
Technavio has published a new market research report on the global liver cirrhosis therapeutics market from 2018-2022. (Photo: Business Wire)
The report will follow up on Technavio’s previous liver cirrhosis therapeutics market report, presenting detailed market intelligence based on an analysis of the recent trends, market drivers, and challenges, to arrive at actionable insights for the forecast period.
The upgraded research report on the global liver cirrhosis therapeutics market is an integral part of Technavio’s portfolio. Technavio covers an extensive range of market research reports on the cardiovascular and metabolic disorders sector, focusing on the development of innovative compounds for novel targets. Some of the topics include biologic therapeutics, peptide therapeutics, inflammatory bowel disease, and type 1 diabetes drugs.
Global opportunities for growth
Technavio’s previous report on the global market projected that the Americas would be the largest market for liver cirrhosis therapeutics by 2020. High incidences of liver diseases such as liver cirrhosis in regions such as the US and Canada is a significant factor that is expected to result in the region’s market share of about 49% by 2020.
In the previous report, a senior research analyst at Technavio stated , “Increased public awareness of liver cirrhosis is a key factor leading to the growth of the market. The early detection of infections is important in reducing disease progression. The early screening and diagnosis of hepatitis C and B infections can prevent or reduce the extent of liver damage. Several government and non-governmental organizations have been organizing awareness campaigns, seminars, summits, and fundraising events to educate people about the diseases and therapeutic measures available. These awareness programs are leading to more people choosing therapeutic drugs for treatment.”
Technavio’s new report on the global liver cirrhosis therapeutics market will evaluate the key geographical regions and their behavior over the past four years, introducing new data and observations and providing new predictions.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Detailed analysis at your fingertips
Some of the topics that will be revisited in the new report include:Market size and growth rate through 2022 Top trends in the market Competitive landscape and market share analysis of the key players Market opportunities and factors hindering growth
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180501005742/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 05/01/2018 03:54 AM/DISC: 05/01/2018 03:54 AM